Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)

Exclusion Criteria

• •Patients with primary lateral sclerosis, progressive muscular atrophy or lower motor neuron disease.
• •Patients who have history of ALS treatment of edaravone or stem cell therapy within 16 weeks before screening.
• •Patients who have permanently ceased the administration of riluzole due to lack of tolerability and/or efficacy.
• •Patients in Class II to IV according to the New York Heart Association functional classification. Patients with myocardial infarction, unstable arrhythmia, and/or significant cardiovascular disease such as unstable angina within 12 weeks before screening.
• •Patients who do not meet the criteria of laboratory tests and medical/operation history.